Literature DB >> 6638746

[The Checklist for Evaluation of Somatic Symptoms (CHESS). Its use in anxious and depressive pathology. Factor structure].

J D Guelfi, C B Pull, C Guelfi, S Ruschel, J F Dreyfus.   

Abstract

The CH.E.S.S. is a new inventory for the assessment of somatic symptoms and complaints. Initialy it included 57 items (43 somatic complaints, 12 neurological signs and 2 "other symptoms"). The CH.E.S.S. was scored before treatment on two groups of patients (133 anxious and 133 depressed) with no schizophrenic or organic symptomatology. 71 somatic complaints or symptoms were identified. A principal component analysis with a subsequent Varimax rotation yelded 25 factors with 18 of clinical significance. 12 factors significantly discriminate between the two groups. Seven factors (21 items) have higher scores in depressed patients: sleep and general somatic disorders, 2) general impairment of intellectual functioning, 3) neurological, 4) neuro-muscular hypo-excitability, 5) lower limbs oedema-amimia, 6) and 7) digestive. Five factors (18 items) have higher scores in anxious patients: 1) and 2) autonomic hyperactivity, 3) neuro-muscular hyper-excitability, 4) digestive, 5) micturition disorders with limb paresthesias. According to these results the 67 items new version of the check-list (CH.E.S.S. 82) includes 51 somatic complaints or symptoms and 16 neurological signs.

Entities:  

Mesh:

Year:  1983        PMID: 6638746

Source DB:  PubMed          Journal:  Ann Med Psychol (Paris)        ISSN: 0003-4487            Impact factor:   0.380


  2 in total

1.  Comparison of the clinical hypnotic effects of zopiclone and triazolam.

Authors:  E Autret; F Maillard; A Autret
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

2.  Carbamazepine and its 10,11-epoxide metabolite in acute mania: clinical and pharmacokinetic correlates.

Authors:  P Petit; R Lonjon; M Cociglio; A Sluzewska; J P Blayac; B Hue; R Alric; R Pouget
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.